Beyond Air Inc. (XAIR)

$3.53

up-down-arrow $-0.06 (-1.67%)

As on 04-Sep-2026 16:22EDT

Market cap

info icon

$3 Mln

Revenue (TTM)

info icon

$8 Mln

P/E Ratio

info icon

0

P/B Ratio

info icon

1.8

Div. Yield

info icon

0 %

Beyond Air (XAIR) Share Price

Compare

High: Low: Return:

Max: Min: Median:

Max: Min: Median:

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 3.50 High: 3.64

52 Week Range

Low: 3.50 High: 177.72

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -5.2 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    46.09

  • EV/EBITDAEV/EBITDA information

    -4.2

  • Debt to EquityDebt to Equity information

    3.8

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-54.3

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    984,407

10 Years Aggregate

CFO

$-101.13 Mln

EBITDA

$-146.13 Mln

Net Profit

$-176.56 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Beyond Air (XAIR)
-75.7 -44.2 -60.0 -92.4 -85.9 -75.7 --
BSE Sensex
-9.6 -2.7 2.9 -5.0 5.4 5.7 10.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 04-Sep-2026  |  #As on 26-Oct-2023
Company
2025
2024
2023
2022
2021
2020
2019
Beyond Air (XAIR)
-89.9 -81.5 -69.8 -31.3 79.1 0.8 12.5
S&P Small-Cap 600
4.0 7.0 13.9 -17.4 25.3 9.6 20.9
BSE Sensex
9.1 8.1 18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Beyond Air (XAIR)
3.5 3.5 7.7 -33.5 -348.7 -648.9 0 1.8
62.7 8,162.7 616.9 -75.1 1.7 -9.3 -- 10.0
15.0 10,125.1 6,561.1 -578.0 -4.5 -10.3 -- 1.8
365.1 9,761.6 2,589.3 222.4 -6.0 3 44.5 1.4
58.5 8,913.0 3,499.6 -71.2 0.5 -3.2 -- 3.8
177.5 10,637.8 612.8 -188.1 -30.6 -28.1 -- 15.3
101.0 6,590.6 1,556.3 275.3 24.6 22.9 24.2 5.0
89.6 5,350.1 1,579.2 145.6 14.3 8.9 36.9 3.2
322.2 12,649.5 1,504.9 160.6 13.6 10.9 79.3 8.3
167.6 9,458.6 785.1 41.5 9.9 2 232.8 4.6

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Beyond Air (XAIR)

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension...  of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York. 

  • CEO & Chairman of the Board

    Mr. Steven Adam Lisi

  • CEO & Chairman of the Board

    Mr. Steven Adam Lisi

  • Headquarters

    Garden City, NY

  • Website

    https://www.beyondair.net

FAQs for Beyond Air (XAIR)

The share price of Beyond Air Inc (XAIR) is $3.53 (NASDAQ) as of 04-Sep-2026 16:22 EDT. Beyond Air Inc (XAIR) has given a return of -85.93% in the last 3 years.

The P/E ratio of Beyond Air Inc (XAIR) is 0.01 times as on 04-Sep-2026, a 100 discount to its peers’ median range of 46.09 times.
The P/B ratio of Beyond Air Inc (XAIR) is 1.76 times as on 04-Sep-2026, a 54 discount to its peers’ median range of 3.79 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2026
-0.17
0.94
2025
0.00
0.00
2024
0.00
0.01
2023
-3.72
4.94
2022
-3.97
2.19

The 52-week high and low of Beyond Air Inc (XAIR) are Rs 177.72 and Rs 3.50 as of 06-Sep-2026.

Beyond Air Inc (XAIR) has a market capitalisation of $ 3 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Beyond Air Inc (XAIR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.

loading...
loading...